Table of Contents
ISRN Microbiology
Volume 2011, Article ID 797463, 4 pages
http://dx.doi.org/10.5402/2011/797463
Research Article

Genetic Diversity and Drug Resistance Mutations in HIV-1 from Untreated Patients in Niamey, Niger

1Laboratory of Bacteriology-Virology, Faculty of Health Sciences, Abdou Moumouni University, P.O. Box 237, Niamey, Niger
2National Reference Laboratory for STI/HIV/TB, P.O. Box 10 146, Niamey, Niger
3Centre de Traitement Ambulatoire (CTA) of Niamey, P.O. Box 11 236, Niamey, Niger
4Solidarité Thérapeutique et Initiative Contre le Sida (SOLTHIS), P.O. Box 10 393, Niamey, Niger

Received 10 August 2011; Accepted 17 September 2011

Academic Editors: A. L. Chenine and M. Shehu-Xhilaga

Copyright © 2011 Saïdou Mamadou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. L. Robertson, J. P. Anderson, J. A. Bradac et al., “HIV-1 nomenclature proposal,” Science, vol. 288, no. 5463, pp. 55–57, 2000. View at Google Scholar · View at Scopus
  2. S. Mamadou, R. M. Cissé, A. R. Ali Maazou et al., “Séroprévalence de l’infection à VIH en population générale au Niger en 2006,” Annales de l’Université Abdou Moumouni de Niamey, vol. XI-A, pp. 20–23, 2010. View at Google Scholar
  3. S. Mamadou, C. Montavon, A. Ben et al., “Predominance of CRF02-AG and CRF06-cpx in Niger, West Africa,” AIDS Research and Human Retroviruses, vol. 18, no. 10, pp. 723–726, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. J. D. Thompson, D. G. Higgins, and T. J. Gibson, “CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice,” Nucleic Acids Research, vol. 22, no. 22, pp. 4673–4680, 1994. View at Google Scholar · View at Scopus
  5. V. A. Johnson, F. Brun-Vézinet, B. Clotet et al., “Update of the drug resistance mutations in HIV-1: December 2010,” Topics in HIV Medicine, vol. 18, no. 5, pp. 156–163, 2010. View at Google Scholar
  6. R. W. Shafer, S. Y. Rhee, D. Pillay et al., “HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance,” AIDS, vol. 21, no. 2, pp. 215–223, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. F. Barin, L. Meyer, R. Lancar et al., “Development and validation of an immunoassay for identification of recent human immunodeficiency virus type 1 infections and its use on dried serum spots,” Journal of Clinical Microbiology, vol. 43, no. 9, pp. 4441–4447, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Mamadou, N. Vidal, C. Montavon et al., “Emergence of complex and diverse CRF02-AG/CRF06-cpx recombinant HIV type 1 strains in Niger, West Africa,” AIDS Research and Human Retroviruses, vol. 19, no. 1, pp. 77–82, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. S. J. Little, S. Holte, J. P. Routy et al., “Antiretroviral-drug resistance among patients recently infected with HIV,” The New England Journal of Medicine, vol. 347, no. 6, pp. 385–394, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. E. S. Daar and D. D. Richman, “Confronting the emergence of drug-resistant HIV type 1: impact of antiretroviral therapy on individual and population resistance,” AIDS Research and Human Retroviruses, vol. 21, no. 5, pp. 343–357, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Derache, A. I. Maiga, O. Traore et al., “Evolution of genetic diversity and drug resistance mutations in HIV-1 among untreated patients from Mali between 2005 and 2006,” Journal of Antimicrobial Chemotherapy, vol. 62, no. 3, pp. 456–463, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Ayouba, T. T. X. Lien, J. Nouhin et al., “Low prevalence of HIV type 1 drug resistance mutations in untreated, recently infected patients from burkina Faso, Côte d'Ivoire, senegal, Thailand, and Vietnam: the ANRS 12134 study,” AIDS Research and Human Retroviruses, vol. 25, no. 11, pp. 1193–1196, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. A. F. Aghokeng, L. Vergne, E. Mpoudi-Ngole et al., “Evaluation of transmitted HIV drug resistance among recently-infected antenatal clinic attendees in four Central African countries,” Antiviral Therapy, vol. 14, no. 3, pp. 401–411, 2009. View at Google Scholar · View at Scopus
  14. N. Ndembi, F. Lyagoba, B. Nanteza et al., “Transmitted antiretroviral drug resistance surveillance among newly HIV type 1-diagnosed women attending an antenatal clinic in Entebbe, Uganda,” AIDS Research and Human Retroviruses, vol. 24, no. 6, pp. 889–895, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. H. Bussmann, F. de la Hoz Gomez, T. H. Roels et al., “Prevalence of transmitted HIV drug resistance in Botswana: lessons learned from the HIVDR-threshold survey conducted among women presenting for routine antenatal care as part of the 2007 national sentinel survey,” AIDS Research and Human Retroviruses, vol. 27, no. 4, pp. 365–372, 2011. View at Publisher · View at Google Scholar
  16. K. Kamoto and J. Aberle-Grasse, “Surveillance of transmitted HIV drug resistance with the World Health Organization threshold survey method in Lilongwe, Malawi,” Antiviral Therapy, vol. 13, supplement 2, pp. 83–87, 2008. View at Google Scholar · View at Scopus
  17. G. Maphalala, V. Okello, S. Mndzebele et al., “Surveillance of transmitted HIV drug resistance in the Manzini-Mbabane corridor, Swaziland, in 2006,” Antiviral Therapy, vol. 13, no. 2, pp. 95–100, 2008. View at Google Scholar · View at Scopus
  18. J. M. Whitcomb, N. T. Parkin, C. Chappey, N. S. Hellmann, and C. J. Petropoulos, “Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates,” Journal of Infectious Diseases, vol. 188, no. 7, pp. 992–1000, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. K. Diallo, M. Götte, and M. A. Wainberg, “Molecular impact of the M184V mutation in human immunodeficiency virus type 1 reverse transcriptase,” Antimicrobial Agents and Chemotherapy, vol. 47, no. 11, pp. 3377–3383, 2003. View at Publisher · View at Google Scholar
  20. E. R. Lanier, N. Givens, C. Stone et al., “Effect of concurrent zidovudine use on the resistance pathway selected by abacavir-containing regimens,” HIV Medicine, vol. 5, no. 6, pp. 394–399, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Y. Rhee, J. Taylor, G. Wadhera, A. Ben-Hur, D. L. Brutlag, and R. W. Shafer, “Genotypic predictors of human immunodeficiency virus type 1 drug resistance,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 46, pp. 17355–17360, 2006. View at Publisher · View at Google Scholar · View at Scopus